Natera, AFT launch phase III breast cancer trial

Natera's initiation of a Phase 3 breast cancer clinical trial in collaboration with AFT is positive in terms of pipeline expansion.

AI CATALYST SCORE60 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

ANALYSIS HISTORY

NTRA Analysis History (Last 30 Days)

Diagnosed At	Ticker	AI Score	Tier
2026-10-21 02:08:07	NTRA	35	Row	View Report →
2026-10-17 02:09:26	NTRA	40	Row	View Report →
2026-10-05 12:17:10	NTRA	60	Mid	View Report →

RELATED REPORTS

Diagnosed At	Ticker	AI Score	Tier
2026-10-25 21:09:52	AGEN	85	Mid	View Report →
2026-10-25 20:13:30	XNCR	80	Mid	View Report →
2026-10-25 19:00:44	GMAB	60	Mid	View Report →
2026-10-25 18:43:11	SMMT	85	Mid	View Report →
2026-10-25 16:22:07	AZN	82	Mid	View Report →
2026-10-25 12:05:03	MRNA	45	Mid	View Report →
2026-10-25 11:15:41	GMAB	50	Mid	View Report →
2026-10-25 08:49:05	XNCR	45	Mid	View Report →
2026-10-24 19:59:13	AMGN	62	Mid	View Report →
2026-10-24 18:08:27	ZYME	64	Mid	View Report →
2026-10-24 14:39:24	AMGN	90	Mid	View Report →
2026-10-24 14:16:22	LLY	65	Mid	View Report →
2026-10-24 12:28:05	MRNA	65	Mid	View Report →
2026-10-24 05:57:34	ALLO	30	Row	View Report →
2026-10-24 01:58:48	VRTX	60	Mid	View Report →
2026-10-23 20:03:59	BMY	45	Mid	View Report →
2026-10-23 19:12:59	IOVA	62	Mid	View Report →
2026-10-23 19:02:09	MRNA	50	Mid	View Report →
2026-10-23 16:30:29	MRNA	60	Mid	View Report →
2026-10-23 16:00:41	MRNA	45	Mid	View Report →
2026-10-23 14:52:37	ALNY	68	Mid	View Report →
2026-10-23 09:05:25	MRNA	25	Row	View Report →
2026-10-23 06:33:51	ZLAB	40	Row	View Report →
2026-10-23 02:12:35	UTHR	42	Row	View Report →
2026-10-23 01:00:24	RAPP	55	Mid	View Report →
2026-10-22 21:53:58	MRNA	50	Mid	View Report →
2026-10-22 19:42:35	MRNA	45	Mid	View Report →
2026-10-22 17:39:22	MRNA	45	Mid	View Report →
2026-10-22 15:17:00	MRNA	55	Mid	View Report →
2026-10-22 13:42:28	LNTH	45	Mid	View Report →